“Nearmedic” starts production of the new drug protivotuberkuleznoe

The company “nearmedic” is preparing to release the pharmaceutical substance of the new anti-TB drug magazinea. The drug developed by GK “nearmedic” and the Swiss École Polytechnique Fédérale de Lausanne (EPFL) jointly with the international Fund Innovative medicines for tuberculosis (Im4TB).

In the near future the production site full cycle of the ASF magazinea (PBTZ 169) will be fully ready for the launch of a new production site research and production complex of OOO “nearmedic Pharma” in Obninsk.

Experimental magazine was a series of studies in Russia and the EU, which has been proven the safety and efficacy of its use in the treatment of tuberculosis with multiple and extensively drug-resistant. The research was conducted in 2014. At the moment, completing a full cycle of preclinical studies a series of clinical trials phase I in healthy volunteers and clinical phase II study investigating the efficacy and safety of the drug magazine when used in patients with newly diagnosed tuberculosis of respiratory organs.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]